The Event. Immatics reported Q2 2026 this morning and, buried inside the business update, changed the single most important date on the calendar. The interim PFS analysis for the pivotal SUPRAME Phase 3 trial — the event I called “the binary event” in my June 1 update — no longer exists. It has been folded into one streamlined final analysis, with topline disclosure now expected in 1H 2027 and the BLA following later in 2027.
The Reaction. The stock is at $9.09, down 18.4% from the $11.14 close I wrote about after the ASCO trifecta. The market has been marking down the catalyst clock for weeks; today it got the official confirmation.
The Reality. The stated reason for the change is that PFS events (progression or death) are accruing more slowly than originally modeled. That sentence is a Rorschach test, and how you read it determines whether you’re a buyer or a seller here.
The Receipts
SUPRAME protocol amendment. Immatics intends to replace the previously planned interim and final PFS analyses with a single final analysis at a lower prespecified number of PFS events, while maintaining 90% power on the primary endpoint. Enrollment remains on track to complete required randomizations by year-end 2026.
Why it matters: The 2026 de-risking event I had penciled in is gone. There is now no anzu-cel efficacy checkpoint until 1H 2027. That’s a real extension of the uncertainty window, and the tape has priced it.
Trial size increasing to ~450 patients. Roughly 90 additional patients are being enrolled — not to rescue PFS, but to power the secondary OS endpoint. Management is explicit that the added OS events have no impact on the timing of the final PFS analysis.
Why it matters: This is a commercial-profile decision, not a statistical bailout. A PFS-only label in 2L melanoma is a weaker payer conversation than PFS plus a credible OS story. But it costs money and patients, and it happens while cash burns.
FDA involvement is on the record. The amendments are “based on feedback from the FDA following recent interaction with the agency.” Anzu-cel already carries RMAT and Orphan Drug Designation.
Why it matters: This looks like a negotiated design change with the agency in the room rather than a unilateral goalpost move. That distinction matters for the P-hacking check — and it’s the single most reassuring line in the release.
Cash: $448.2M (€393.4M) as of June 30, 2026, down from $534.7M (€469.3M) at year-end 2025. H1 operating cash outflow was €102.5M. R&D jumped to €62.4M in Q2 from €45.1M a year ago, driven by SUPRAME. The company drew $25.0M on the ATM at $10.02/share in March. Cash reach is still guided into 2028.
Why it matters: The fortified balance sheet I described in March is thinner but not broken. Runway into 2028 still clears the 1H 2027 topline and a 2027 BLA submission. The ATM draw at $10.02 is a reminder that the tap is open and will get used.
Moderna milestone triggered. The first patient was dosed in July 2026 in a Moderna-sponsored trial of mRNA-4200, a candidate discovered under the Database Program using XPRESIDENT® and the XCUBE® bioinformatics platform. A €0.5M Database milestone was recognized in Q2; collaboration revenue rose to €9.1M from €4.7M year-over-year.
Why it matters: Small dollars, real validation. The target-discovery engine produced something a large partner put into humans. It’s non-dilutive optionality, not a thesis pillar.
General Counsel transition. Edward Sturchio stepped down; Jim Pepin (ex-Legend Biotech, ex-Aimmune) took the role July 20, 2026.
Why it matters: Hiring the former GC of a commercial-stage cell therapy company is the tea leaf. You bring in that skill set when you’re building for a launch, not a wind-down.
The Scientific Reality Check
Here’s the part worth slowing down for, because “PFS events are occurring more slowly than modeled” can mean two opposite things.
